Drug profile · INN
ombitasvir
VIEKIRAX
ombitasvir (VIEKIRAX) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ombitasvir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
ombitasvir (VIEKIRAX) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nonstructural protein 5A inhibitor
Primary target: Nonstructural protein 5A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is ombitasvir?
ombitasvir (VIEKIRAX) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ombitasvir?
VIEKIRAX is a marketed brand name for ombitasvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ombitasvir?
ombitasvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.